Male contraception is finally coming — and it might be here as soon as 2018. Vasalgel, a non-hormonal male contraceptive owned by the medical research organization the Parsemus Foundation is poised as the first FDA-approved male contraceptive since the condom. One injection of Vasalgel — a polymer that’s injected under local anesthetic into the man’s sperm-carrying tubes, accessible through the scrotum — could last for several years. It works by blocking sperm and is expected to be reversible through a second injection that dissolves the polymer. It’s length of efficacy will be tested during medical trials, which start in 2016 and the contraceptive is estimated to hit the U.S. market between 2018 and 2020. Other male contraceptives are underway as well: there is Gendarussa which would prevent the sperm’s ability to fertilise an egg, an anti-Eppin agent which prevents sperm from swimming, and – probably most controversial, the “Clean Sheets Pill.” Yes, you’ve guessed that right: that drug is designed “to allow orgasm while inhibiting ejaculation.” While none of those have gone past the clinical trial phases, male contraception is slowly but surely becoming inevitable, and bound to change a lot of lives, as well as the way we think about sex and relationships.
Read the full story at The Telegraph.